<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131163">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958177</url>
  </required_header>
  <id_info>
    <org_study_id>CSCC/BMCA/2013//01</org_study_id>
    <nct_id>NCT01958177</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Efficacy Mesenchymal Stem Cell in Cerebellar Ataxia</brief_title>
  <official_title>Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cell in Cerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chaitanya Hospital, Pune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chaitanya Hospital, Pune</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebellar ataxia is a complex motor disturbance, which, can occur as a result of many
      diseases and presents with symptoms of an inability to coordinate balance, gait, extremity
      and eye movements. Lesions to the cerebellum can cause dyssynergia, dysmetria,
      dysdiadochokinesia, dysarthria and ataxia of stance and gait. Deficits are observed with
      movements on the same side of the body as the lesion (ipsilaterally).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>improve in INTERNATIONAL CO-OPERATIVE ATAXIA RATING SCALE</measure>
    <time_frame>baseline and after 12 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To see improvement in INTERNATIONAL CO-OPERATIVE ATAXIA RATING SCALE when compare with baseline and after 12 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Balance test</measure>
    <time_frame>baseline and after 12 MONTH</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To see improvement in Balance test when compare with baseline and after 12 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremor Rating Scale</measure>
    <time_frame>baseline and after 12 MONTH</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>compare the pre and post Tremor Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cerebellar Ataxia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous transfer of Mesenchymal Stem Cell ( MSCs )</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous transfer of Mesenchymal Stem Cell ( MSCs )</intervention_name>
    <description>Total 6 doses ,in 30 days ,in 7days interval Intravenous transfer of Bone marrow derived  Mesenchymal Stem Cell ( MSCs )</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age limit: 18 -65

          -  Diagnosed as Cerebellar ataxia

          -  Willingness to undergo Bone marrow and umbilical cord derived Mesenchymal stem cell
             transplantation.

          -  To give an informed consent as well as sign the required Informed Consent Form (ICF)
             for the study.

          -  willingness to regularly visit the hospital / clinic for follow up during the follow
             up period / on prior agreed time points as per the protocol.

        Exclusion Criteria:

          -  Patients with pre-existing or current systemic disease such as lung , liver
             (exception: history of uncomplicated hepatitis A) gastrointestinal , cardiac,
             immunodeficiency (including HIV) or any other condition determined by history or
             laboratory investigation that could cause a neurological defect (including syphilis,
             clinically relevant polyneuropathy) etc.

          -  Women who are pregnant or lactating

          -  Chronic kidney disease due to autoimmune aetiology, connective tissue disease,
             amyloidosis and storage disorders.

          -  Suffering from Severe co-morbidities like cardiac insufficiency, congestive cardiac
             failure, malignancy, infection, sepsis and bed sores.

          -  Positive test results for HIV and AIDS complex ,HCV , HbsAg and Syphilis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANANT E BAGUL, MS ORTHO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaitanya Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin P Jamadar, D.Ortho</last_name>
    <phone>918888788880</phone>
    <email>sac2751982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Smita S Bhoyar, B.A.M.S.PGCR</last_name>
    <phone>9372620569</phone>
    <email>drsmitabhoyar@rediff.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaitanya Hospital</name>
      <address>
        <city>Pune,</city>
        <state>Maharashtra</state>
        <zip>411030</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sachin P Jamadar, D ORTHO</last_name>
      <phone>+918888788880</phone>
      <email>sac2751982@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anant E Bagul, MS,Ortho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chaitanya Hospital, Pune</investigator_affiliation>
    <investigator_full_name>Dr. Sachin Jamadar</investigator_full_name>
    <investigator_title>Co -investigator</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>cerebellar ataxia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
